Literature DB >> 9697824

Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease.

P H Pak1, W L Maughan, K L Baughman, R S Kieval, D A Kass.   

Abstract

BACKGROUND: Dual-chamber pacing can improve symptoms in hypertrophic cardiomyopathy (HCM), but the mechanism remains unclear. We hypothesized that pacing generates discoordinate contraction and a rightward shift of the end-systolic pressure-volume relation (ESPVR) and that benefits from this mechanism do not depend on the presence of resting outflow pressure gradients or obstruction. METHODS AND
RESULTS: Eleven patients with NYHA class III symptoms, 5 with HCM, and 6 with hypertensive hypertrophy and cavity obliteration, were studied by invasive conductance catheter methods. No patient had coronary artery or primary valvular disease. Pressure-volume relations were recorded before and during VDD pacing by use of a short (75-millisecond) PR interval to achieve preexcitation. Left ventricular cavity pressure was simultaneously recorded at basal and apical sites, with pressure at the basal site used to generate the ESPVRs. VDD pacing shifted the ESPVR rightward, increasing end-systolic volume by 45% (range, 17% to 151%; P=0.002). Resting and provokable gradients declined by 20% (range, -56% to +3%) and 30% (range, -65% to -12%), respectively (P<0.05). Preload declined by 3% to 10% because of the short PR interval. Preload-corrected contractility indexes and myocardial workload declined by approximately 10% (P<0.001). Diastolic compliance and relaxation time were unchanged. Pacing made apical pressure-volume loops discoordinate, limiting cavity obliteration and reducing distal systolic pressures. Results in both patient groups were similar.
CONCLUSIONS: VDD pacing shifts the ESPVR rightward in HCM patients with cavity obliteration with or without obstruction, increasing end-systolic volumes and reducing apical cavity compression and cardiac work. These effects likely contribute to reduced metabolic demand and improved symptoms.

Entities:  

Mesh:

Year:  1998        PMID: 9697824     DOI: 10.1161/01.cir.98.3.242

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Electrical modulation of cardiac contractility: clinical aspects in congestive heart failure.

Authors:  C Pappone; G Vicedomini; A Salvati; C Meloni; W Haddad; R Aviv; Y Mika; N Darvish; Y Kimchy; I Shemer; Y Snir; D Pruchi; S A Ben-Haim; I Kronzon
Journal:  Heart Fail Rev       Date:  2001-01       Impact factor: 4.214

4.  Left ventricular function and the systemic arterial vasculature: remembering what we have learned.

Authors:  Brian P Davidson; George D Giraud
Journal:  J Am Soc Echocardiogr       Date:  2012-08       Impact factor: 5.251

Review 5.  Alpha-tropomyosin mutations in inherited cardiomyopathies.

Authors:  Charles Redwood; Paul Robinson
Journal:  J Muscle Res Cell Motil       Date:  2013-09-05       Impact factor: 2.698

6.  Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients.

Authors:  Antonio Berruezo; Markus Linhart; Angelo Auricchio; José Luis Zamorano; Pilar Santamaria; Roger Borràs; Felip Burgos; Josep Brugada
Journal:  J Interv Card Electrophysiol       Date:  2018-02-03       Impact factor: 1.900

7.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

8.  Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.

Authors:  Jan-Christian Reil; Mathias Hohl; Gert-Hinrich Reil; Henk L Granzier; Mario T Kratz; Andrey Kazakov; Peter Fries; Andreas Müller; Matthias Lenski; Florian Custodis; Stefan Gräber; Gerd Fröhlig; Paul Steendijk; Hans-Ruprecht Neuberger; Michael Böhm
Journal:  Eur Heart J       Date:  2012-07-24       Impact factor: 29.983

9.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.

Authors:  Takahiro Nagayama; Steven Hsu; Manling Zhang; Norimichi Koitabashi; Djahida Bedja; Kathleen L Gabrielson; Eiki Takimoto; David A Kass
Journal:  J Am Coll Cardiol       Date:  2009-01-13       Impact factor: 24.094

10.  Myocardial ischemia with left ventricular outflow obstruction.

Authors:  Aron F Popov; Christian Bireta; Jan D Schmitto; Dieter Zenker; Martin Friedrich; Kasim O Coskun; Ralf Seipelt; Gerd G Hanekop; Friedrich A Schoendube
Journal:  J Cardiothorac Surg       Date:  2009-09-17       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.